This is a working overview of circadian clock, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-14 and is reviewed periodically as new material appears.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
=== 1997 Georgia === In 1997, several Georgian soldiers suffered radiation poisoning and burns. They were eventually traced back to training sources left abandoned, forgotten, and unlabelled after the dissolution of the Soviet Union. One was a caesium-137 pellet in a pocket of a shared jacket that released about 130,000 times the level of background radiation at a 1-metre (3-foot) distance.
X Both the First and Second Ministries were officially referred to as the "Court–Cowan Ministry" or "Court Ministry" in Hansard and other parliamentary records. 1 On 24 August 1993, Doug Shave resigned for personal reasons. His three portfolios were distributed to three of the other ministers. 2 On 25 January 1994, the ministry returned to 17 members with the appointment of Kevin Prince. Additionally, the Premier took on the role of Minister for Tourism. 3 On 26 April 1994, parliamentary secretary Bob Pike died. His parliamentary secretary position was not refilled.
The Colombian Football Federation appointed Pinto as Rueda's successor in December 2006. Colombia were eliminated in the group stage of the 2007 Copa América, before Pinto was dismissed in September 2008 following a 1–0 home defeat by Uruguay and a 4–0 loss to Chile in Santiago. Lara, formerly the federation's youth-team coach, initially replaced him on an interim basis. Under Lara, Colombia finished seventh of ten teams in the 2010 World Cup qualifiers, with 23 points and 14 goals in 18 matches. They were level on points and goal difference with sixth-placed Ecuador, but ranked below them on goals scored. A 4–2 home defeat to Chile on 10 October 2009 confirmed elimination, and Lara resigned after the campaign.
Sources: en.wikipedia.org
==== Energy ==== In August 2026, Talarico released an energy plan which proposed investments in oil and gas, nuclear, wind, solar, and geothermal energy and was described as an "all-of-the-above" policy. In August 2026, Talarico announced a "Hold Data Centers Accountable Plan", which included ending tax incentives for data centers, requiring data centers to pay for infrastructure and grid interconnection costs, requiring data centers to use closed-loop water systems, and allowing communities to approve or reject data center projects in their area. He proposed a plan to suspend federal gas and diesel taxes after prices rose due to the 2026 Iran war.
=== Growth-related === TCTP has properties of a tubulin binding protein that associates with microtubules in a cell cycle-dependent manner. The transient overexpression of TCTP in HeLa cells prevented them from undergoing etoposide-induced apoptosis. Expressing TCTP in U2OS (human bone osteosarcoma epithelial cells) protected them from cell death induced by etoposide over various concentrations and durations of exposure. TCTP overexpression inhibited caspase-3-like activity as assessed by the cleavage of fluorogenic substrate. Expression levels of TCTP were down-regulated at the mRNA and protein levels during tumor suppression and by the activation of p53 and Siah-1 very well known anti-tumor genes. Down-regulation of TCTP can induce tumor reversion, and in combination with some drugs that decrease the level of TCTP and will lead to kill tumor cells. TCTP knockdown in primary mammary tumor cells, results in increased p53 expression and a decreased number of stem-like cancer cells. Reducing TCTP (dTCTP) levels in Drosophila reduces cell size, cell number and organ size, which mimics Drosophila Rheb (dRheb) mutant phenotypes; human TCTP (hTCTP) shows similar biochemical properties compared to dTCTP.
=== 2010s === In January 2010, Sonic announced that they would begin switching to battery cage-free eggs, gestation crate-free pork, and chickens killed using controlled-atmosphere stunning methods instead of traditional shackling and electrical stunning. The company has subsequently backtracked on these commitments and now faces public criticism. Sonic reformulated its soft-serve ice cream to meet the FDA standards of identity that define what constitutes real ice cream and introduced Real Ice Cream on May 17, 2010. Several new hot dog items were also introduced in June 2010 and February 2011. Craig Miller was hired as chief information officer in January 2012. In June 2010, Danielle Vona was hired as chief marketing officer. In late 2010, Sonic announced the end of its 17-year relationship with advertising agency Barkley. A group of specialized agencies was selected to represent the company, and in early 2011, San Francisco-based Goodby Silverstein and Partners was named as the new creative agency for the company. In 2017, Sonic announced it would add seven new stores in Hawaii in the near future. However, its first location in the state would not open unilt May 2026 with a single location in Kapolei. In September 2017, Sonic opened its first location in Alaska in Wasilla, and a year later it opened its second Alaska location in Fairbanks. On September 25, 2018, Atlanta-based Inspire Brands, owner of Arby's and Buffalo Wild Wings, announced that it would acquire Sonic for $2.3 billion. The acquisition was completed on December 7, 2018. While he was with the St.
Sources: en.wikipedia.org
Christian missions also became an important way for spreading Western-style music in Meiji era. In the sixteenth century Portuguese missionaries introduced the first Western-style music to Japan: sacred choral music, music for organ, flute, harp, trumpet, violin, alto, double bass. However, soon Christianity, along with its institutions, was banned. In the Meiji era, the ban of Christianity was lifted. Thus, Catholic, Orthodox and Protestant missionaries started actively preaching, and the introduction of sacred music became an integral part of their activities. The Orthodox mission introduced traditional choral music in Japan. The great impact in the choral music development was made by musicians such as conductors Iacob Tihai (served in the Orthodox mission from 1874 to 1886) and Dmytro Livovsky (served in the Orthodox mission from 1880 to 1921). They organized the first traditional choirs in Holy Resurrection Cathedral in Tokyo (known as Nikolai-do), taught music in Tokyo Theological Seminary, completed and published the first musical score collections, and educated the first Japanese choir conductors and music teachers. Among them are Roman Chiba, Alexey Obara, Innokentiy Kisu, Yakov Maedako, Petr Tokairin, Ioan Nakashima, Moisei Kawamura, Ioan Owata, Pavel Isiya, Vasiliy Takeda, Andrey Abe, Alexandr Komagai, Fedor Minato, Alexey Sawabe, Luka Orit. All of them became Orthodox Christians and adopted Christian names.
His position has mostly been met with negative comments across the media and sports press due to the NFL having as many as 4,500 former players reporting symptoms of CTE. More recently, he has been investigating the therapeutic effects of hyperbaric oxygen therapy (HBO) in various neurological conditions, including post-concussion syndrome, PTSD, traumatic brain injury, stroke, and spinal cord injury. Maroon was asked to testify to the New York City Council on a proposed rule on sideline medical coverage for organized youth football in the city. Together with Russell Blaylock, he developed an inflammation hypothesis for the biochemical mechanisms involved in the development of CTE following head trauma. In the 2015 movie Concussion, which "examines how American football players suffer from major head injuries and life-long debilitating problems as a result of repeated concussions, and efforts by the National Football League to deny it," Maroon was played by actor Arliss Howard. In the movie, Maroon is portrayed as an NFL-biased doctor who tries to deny any relationship between football concussions and the brain pathology that Dr. Bennet Omalu found and attributed to CTE. Since the release of the movie, several people have come forward in defense of Maroon, stating that his portrayal in the movie is sensationalized and incorrect.
Host cell proteins (HCPs) are process-related protein impurities that are produced by the host organism during biotherapeutic manufacturing and production. During the purification process, a majority of produced HCPs are removed from the final product (>99% of impurities removed). However, residual HCPs still remain in the final distributed pharmaceutical drug. Examples of HCPs that may remain in the desired pharmaceutical product include: monoclonal antibodies (mAbs), antibody-drug-conjugates (ADCs), therapeutic proteins, vaccines, and other protein-based biopharmaceuticals. HCPs may cause immunogenicity in individuals or reduce the potency, stability or overall effectiveness of a drug. National regulatory organisations, such as the FDA and EMA provide guidelines on acceptable levels of HCPs that may remain in pharmaceutical products before they are made available to the public. The accepted level of HCPs in a final product is evaluated on a case-by-case basis, and depends on multiple factors including: dose, frequency of drug administration, type of drug and severity of disease. The acceptable range of HCPs in a final pharmaceutical product is large due to limitations with the detection and analytical methods that currently exist. Analysis of HCPs is complex as the HCP mixture consists of a large variety of protein species, all of which are unique to the specific host organisms, and unrelated to the intended and desired recombinant protein.
Organic chemists use the tools of thermodynamics to study the bonding, stability, and energetics of chemical systems. This includes experiments to measure or determine the enthalpy (ΔH), entropy (ΔS), and Gibbs' free energy (ΔG) of a reaction, transformation, or isomerization. Chemists may use various chemical and mathematical analyses, such as a Van 't Hoff plot, to calculate these values. Empirical constants such as bond dissociation energy, standard heat of formation (ΔfH°), and heat of combustion (ΔcH°) are used to predict the stability of molecules and the change in enthalpy (ΔH) through the course of the reactions. For complex molecules, a ΔfH° value may not be available but can be estimated using molecular fragments with known heats of formation. This type of analysis is often referred to as Benson group increment theory, after chemist Sidney Benson who spent a career developing the concept. The thermochemistry of reactive intermediates—carbocations, carbanions, and radicals—is also of interest to physical organic chemists. Group increment data are available for radical systems. Carbocation and carbanion stabilities can be assessed using hydride ion affinities and pKa values, respectively.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.